Allergan plc (AGN)


NYSE - NYSE Real Time Price. Currency in USD
236.31-6.96 (-2.86%)
At close: 4:01 PM EDT

236.31 0.00 (0.00%)
After hours: 4:29 PM EDT

People also watch:
BIIBCELGVRXGILDREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open243.00
Prev Close243.27
Bid236.51 x 100
Ask237.10 x 400
Day's Range232.10 - 244.27
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap93.57B
P/E Ratio (ttm)22.50
Beta1.11
Volume6,101,424
Avg Vol (3m)3,123,604
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Associated Press31 minutes ago

    Markets Right Now: Health care pulls stocks lower again

    The latest on developments in global financial markets (all times local): 4:00 p.m. More declines in health care stocks are pulling indexes lower on Wall Street. Biotechnology companies continued to fall ...

  • Moody's2 hours ago

    Teva Pharmaceutical Industries Ltd -- Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative

    New York, August 25, 2016-- Moody's Investors Service commented that the Patent Trial and Appeal Board's invalidation of two of Teva's patents on Copaxone 40 mg is credit negative. However, there is no ...

  • Barrons.com3 hours ago

    Specialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out

    While fundamentals of the group appear stable following the recent 2Q16 earnings season (see our recent note here) and valuations are attractive, we acknowledge that ongoing negative headlines may stunt the fledgling “recovery” that has started to take place in the space over the past couple of months. More broadly, while media scrutiny/political headlines around drug pricing could result in continued volatility through the elections, we continue to see the group positioned for a recovery over time, with valuations inexpensive on almost any metric (~8x 2017 EPS) and improving fundamentals after a challenging 1H/16.